Ribonucleotide reductase inhibitors and future drug design
J Shao, B Zhou, B Chu, Y Yen - Current cancer drug targets, 2006 - ingentaconnect.com
Ribonucleotide reductase (RR) is a multisubunit enzyme responsible for the reduction of
ribonucleotides to their corresponding deoxyribonucleotides, which are building blocks for …
ribonucleotides to their corresponding deoxyribonucleotides, which are building blocks for …
ICUD-EAU international consultation on bladder cancer 2012: chemotherapy for urothelial carcinoma—neoadjuvant and adjuvant settings
CN Sternberg, J Bellmunt, G Sonpavde… - European urology, 2013 - Elsevier
CONTEXT: We present a summary of the Second International Consultation on Bladder
Cancer recommendations on chemotherapy for the treatment of bladder cancer using an …
Cancer recommendations on chemotherapy for the treatment of bladder cancer using an …
A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell …
C Wülfing, JPH Machiels, DJ Richel, MO Grimm… - Cancer, 2009 - Wiley Online Library
BACKGROUND: The treatment of recurrent transitional cell carcinoma (TCC) remains an
unmet clinical need. This study assessed lapatinib, a dual tyrosine kinase inhibitor of …
unmet clinical need. This study assessed lapatinib, a dual tyrosine kinase inhibitor of …
Metabolism and transport of oxazaphosphorines and the clinical implications
J Zhang, Q Tian, S Yung Chan, S Chuen Li… - Drug metabolism …, 2005 - Taylor & Francis
The oxazaphosphorines including cyclophosphamide (CPA), ifosfamide (IFO), and
trofosfamide represent an important group of therapeutic agents due to their substantial …
trofosfamide represent an important group of therapeutic agents due to their substantial …
In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant
AM Bergman, PP Eijk, VWT Ruiz van Haperen, K Smid… - Cancer research, 2005 - AACR
Gemcitabine is a deoxycytidine (dCyd) analogue with activity against several solid cancers.
Gemcitabine is activated by dCyd kinase (dCK) and interferes, as its triphosphate dFdCTP …
Gemcitabine is activated by dCyd kinase (dCK) and interferes, as its triphosphate dFdCTP …
Clinical pharmacology of cyclophosphamide and ifosfamide
J Zhang, Q Tian, SF Zhou - Current Drug Therapy, 2006 - ingentaconnect.com
The oxazaphosphorine cyclophosphamide (CPA) and ifosfamide (IFO) are two commonly
used DNAalkylating agents in cancer chemotherapy. This review highlights the …
used DNAalkylating agents in cancer chemotherapy. This review highlights the …
miR‐124 exerts tumor suppressive functions on the cell proliferation, motility and angiogenesis of bladder cancer by fine‐tuning UHRF 1
X Wang, Q Wu, B Xu, P Wang, W Fan, Y Cai… - The FEBS …, 2015 - Wiley Online Library
UHRF 1, an epigenetic factor, is implicated in various cellular processes of tumorigenesis.
However, the modulation of UHRF 1 expression in human bladder cancer at post …
However, the modulation of UHRF 1 expression in human bladder cancer at post …
Associations between exercise and quality of life in bladder cancer survivors: a population-based study
KH Karvinen, KS Courneya, S North, P Venner - … Epidemiology Biomarkers & …, 2007 - AACR
Background: Exercise has been shown to improve quality of life (QoL) in some cancer
survivor groups, but it is unknown if the unique QoL issues faced by bladder cancer …
survivor groups, but it is unknown if the unique QoL issues faced by bladder cancer …
Identification of a synthetic lethal relationship between nucleotide excision repair deficiency and irofulven sensitivity in urothelial cancer
Purpose: Cisplatin-based chemotherapy is a first-line treatment for muscle-invasive and
metastatic urothelial cancer. Approximately 10% of bladder urothelial tumors have a somatic …
metastatic urothelial cancer. Approximately 10% of bladder urothelial tumors have a somatic …
Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer
Background Most bladder cancer patients experience lymphatic metastasis in the course of
disease progression, yet the relationship between lymphangiogenesis and lymphatic …
disease progression, yet the relationship between lymphangiogenesis and lymphatic …